Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC.
EGFR-mutant
epidermal growth factor receptor (EGFR)
lung cancer
non-small cell lung cancer (NSCLC)
resistance
stereotactic body radiation therapy (SBRT)
stereotactic radiosurgery (SRS)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 Aug 2022
18 Aug 2022
Historique:
received:
14
07
2022
revised:
02
08
2022
accepted:
16
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Tyrosine kinase inhibitor (TKI) therapy is the recommended first-line treatment for metastatic non-small-cell lung cancer (NSCLC) positive for epidermal growth factor receptor (EGFR) gene mutation. However, most individuals treated with TKI therapy for EGFR-mutant NSCLC will develop tumor resistance to TKI therapy. Therapeutic strategies to overcome TKI resistance are the topic of several ongoing clinical trials. One potential strategy, which has been explored in numerous trials, is the treatment of progressive sites of disease with stereotactic body radiation treatment (SBRT) or stereotactic radiosurgery (SRS). We sought to review the literature pertaining to the use of local ablative radiation therapy in the setting of acquired resistance to TKI therapy and to discuss stereotactic radiation therapy as a strategy to overcome TKI resistance.
Identifiants
pubmed: 36010982
pii: cancers14163983
doi: 10.3390/cancers14163983
pmc: PMC9406789
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Cancer Treat Rev. 2016 Apr;45:139-62
pubmed: 27019457
J Thorac Dis. 2010 Mar;2(1):48-51
pubmed: 22263017
J Thorac Oncol. 2014 Feb;9(2):154-62
pubmed: 24419411
J Clin Oncol. 2005 Sep 1;23(25):5900-9
pubmed: 16043828
J Clin Oncol. 2018 Aug 28;:JCO2018783118
pubmed: 30153097
Curr Oncol. 2018 Jun;25(Suppl 1):S28-S37
pubmed: 29910645
J Thorac Dis. 2018 Jul;10(7):E526-E531
pubmed: 30174925
JAMA Oncol. 2018 Jan 11;4(1):e173501
pubmed: 28973074
Oncologist. 2019 Aug;24(8):1031-e612
pubmed: 31040256
Cancer Drug Resist. 2020 Feb 28;3(2):171-178
pubmed: 35582610
Front Oncol. 2020 Oct 28;10:595466
pubmed: 33194761
Ann Oncol. 2018 Jan 1;29(suppl_1):i10-i19
pubmed: 29462254
J Thorac Oncol. 2012 Dec;7(12):1807-1814
pubmed: 23154552
Neurosurgery. 2017 Mar 1;80(3):N7-N16
pubmed: 28362974
J Thorac Oncol. 2014 Feb;9(2):195-9
pubmed: 24419416
F1000Res. 2016 Sep 08;5:
pubmed: 27635238
JCO Precis Oncol. 2020 Nov;4:411-425
pubmed: 35050738
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Eur Respir J. 2012 Feb;39(2):366-72
pubmed: 21778168
Cancers (Basel). 2017 Aug 12;9(8):
pubmed: 28805682
Cancer. 2012 Jun 1;118(11):2962-70
pubmed: 22020702
J Clin Oncol. 1995 Jan;13(1):8-10
pubmed: 7799047
J Clin Oncol. 2005 Oct 1;23(28):6829-37
pubmed: 15998907
Transl Oncol. 2018 Oct;11(5):1119-1127
pubmed: 30032006
Oncol Rep. 2015 Mar;33(3):1499-504
pubmed: 25607753
Clin Cancer Res. 2019 Nov 1;25(21):6382-6391
pubmed: 31182434
Ther Adv Med Oncol. 2019 Nov 25;11:1758835919890286
pubmed: 31803256
Zhongguo Fei Ai Za Zhi. 2015 Aug;18(8):475-80
pubmed: 26302343
EBioMedicine. 2019 Mar;41:711-716
pubmed: 30852159
Hum Pathol. 2011 Oct;42(10):1447-53
pubmed: 21497370
Nat Rev Cancer. 2007 Mar;7(3):169-81
pubmed: 17318210
Transl Lung Cancer Res. 2015 Feb;4(1):67-81
pubmed: 25806347
World J Oncol. 2019 Jun;10(3):142-150
pubmed: 31312281
Expert Opin Pharmacother. 2016;17(7):1013-21
pubmed: 26967582
J Clin Oncol. 2005 Apr 10;23(11):2513-20
pubmed: 15738541
Oncogene. 1997 Sep 4;15(10):1191-7
pubmed: 9294612
J Thorac Oncol. 2012 Dec;7(12):1815-1822
pubmed: 23154553
Cancers (Basel). 2017 May 17;9(5):
pubmed: 28513565
Medicine (Baltimore). 2018 Nov;97(44):e13014
pubmed: 30383657
J Clin Oncol. 2017 Apr 1;35(10):1070-1077
pubmed: 28113019
J Clin Oncol. 2018 Sep 10;36(26):2702-2709
pubmed: 30059262
J Clin Oncol. 2014 Dec 1;32(34):3824-30
pubmed: 25349291
Cell Death Dis. 2018 Jan 25;9(2):117
pubmed: 29371589
Oncogene. 2019 Jan;38(4):455-468
pubmed: 30111817
Cancer Res. 2005 Apr 15;65(8):3328-35
pubmed: 15833866
Anticancer Res. 2009 Oct;29(10):4217-21
pubmed: 19846976
Am J Cancer Res. 2014 Nov 19;4(6):608-28
pubmed: 25520855
J Thorac Oncol. 2012 Nov;7(11):1722-7
pubmed: 23059777
Radiother Oncol. 2020 Nov;152:96-100
pubmed: 32745669
Clin Transl Oncol. 2019 Oct;21(10):1424-1431
pubmed: 30864019
J Hematol Oncol. 2019 Dec 9;12(1):134
pubmed: 31815659
Ann Transl Med. 2019 Feb;7(3):61
pubmed: 30906765
Oncotarget. 2016 Nov 29;7(48):78985-78993
pubmed: 27738317
Cancer Med. 2018 Oct;7(10):5315-5321
pubmed: 30259694
J Thorac Oncol. 2013 Mar;8(3):346-51
pubmed: 23407558
Transl Lung Cancer Res. 2015 Feb;4(1):36-54
pubmed: 25806345
Br J Cancer. 2019 Oct;121(9):725-737
pubmed: 31564718
BMC Cancer. 2020 May 1;20(1):370
pubmed: 32357848
In Vivo. 2020 Jul-Aug;34(4):2009-2014
pubmed: 32606174
Ann Oncol. 2018 Mar 1;29(3):687-693
pubmed: 29293889
J Clin Oncol. 2019 Jun 20;37(18):1558-1565
pubmed: 31067138
J Natl Cancer Inst. 2005 May 4;97(9):643-55
pubmed: 15870435
J Clin Oncol. 2020 Sep 1;38(25):2830-2838
pubmed: 32484754